Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.43 |
| ▸ | CTSS | P25774 | 7/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 7/20 | 0.41 |
| ▸ | PPARG | P37231 | 6/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1963143 | 1.00 | CTSK (0.43) | CTSKCTSSCTSLPPARAPPARG | |
| SCHEMBL3613122 | 0.99 | CTSK (0.43) | CTSKCTSSCTSLPPARAPPARG | |
| SCHEMBL8265511 | 0.99 | CTSK (0.43) | CTSKCTSSCTSLPPARAPPARG | |
| SCHEMBL2364176 | 0.97 | CTSK (0.43) | CTSKCTSSCTSLPPARAPPARG | |
| SCHEMBL2364175 | 0.97 | CTSK (0.43) | CTSKCTSSCTSLPPARAPPARG | |
| SCHEMBL29059461 | 0.97 | CTSK (0.43) | CTSKCTSSCTSLPPARAPPARG | |
| SCHEMBL22636134 | 0.94 | CTSS (0.44) | CTSKCTSSCTSLPPARAPPARG | |
| SCHEMBL22636135 | 0.94 | CTSS (0.44) | CTSKCTSSCTSLPPARAPPARG | |
| SCHEMBL6819730 | 0.94 | CTSS (0.44) | CTSKCTSSCTSLPPARAPPARG | |
| SCHEMBL5327858 | 0.88 | CTSL (0.42) | CTSKCTSSCTSLCTSBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102971286-B | New cathepsin S protease inhibitors for the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions | MEDIVIR UK LTD. (GB) | 2015-08-26 | — | — | CN | disclosed |
| EP-2582660-B1 | NEW CATHEPSIN S PROTEASE INHIBITORS, USEFUL IN THE TREATMENT OF E.G. AUTOIMMUNE DISORDERS, ALLERGY AND CHRONIC PAIN CONDITIONS | MEDIVIR UK LTD (GB) | 2015-07-22 | — | — | EP | disclosed |
| US-20150025250-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD | 2015-01-22 | — | — | US | disclosed |
| US-8859605-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8859505-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8853281-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-10-07 | — | — | US | disclosed |
| US-8815809-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-08-26 | — | — | US | disclosed |
| EP-2509956-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2014-07-23 | — | — | EP | disclosed |
| EP-2752404-A1 | Cysteine protease inhibitors | Medivir UK Ltd (GB) | 2014-07-09 | — | — | EP | disclosed |
| US-20130172232-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2013-07-04 | — | — | US | disclosed |
| EP-2582660-A1 | NEW CATHEPSIN S PROTEASE INHIBITORS, USEFUL IN THE TREATMENT OF E.G. AUTOIMMUNE DISORDERS, ALLERGY AND CHRONIC PAIN CONDITIONS | Medivir UK Ltd (GB) | 2013-04-24 | — | — | EP | disclosed |
| WO-2012172473-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2012-12-20 | — | — | WO | disclosed |
| US-20120309673-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2012-12-06 | — | — | US | disclosed |
| US-20120283305-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2012-11-08 | — | — | US | disclosed |
| WO-2011158197-A1 | NEW CATHEPSIN S PROTEASE INHIBITORS, USEFUL IN THE TREATMENT OF E.G. AUTOIMMUNE DISORDERS, ALLERGY AND CHRONIC PAIN CONDITIONS | MEDIVIR UK LIMITED (GB) | 2011-12-22 | — | — | WO | disclosed |
| US-20110312964-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2011-12-22 | — | — | US | disclosed |
| EP-2358692-A1 | CYSTEINE PROTEASE INHIBITORS | Medivir UK Ltd (GB) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010070615-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2010-06-24 | — | — | WO | disclosed |
| WO-2006064286-A1 | CATHEPSIN S INHIBITORS | MEDIVIR UK LTD (GB) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312964-A1 | CYSTEINE PROTEASE INHIBITORS | CTSS, CTSB, CTSV | CTSK 9/4885CTSS 1/4885CTSL 5/4885 |
| US-20150025250-A1 | CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTRB1 | CTSK 13/4885CTSS 2/4885CTSL 9/4885 |
| US-20120309673-A1 | CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTRB1 | CTSK 13/4885CTSS 2/4885CTSL 9/4885 |
| US-20120283305-A1 | CYSTEINE PROTEASE INHIBITORS | CTSS, CTSB, CTRB1 | CTSK 19/4885CTSS 1/4885CTSL 7/4885 |
| US-20130172232-A1 | CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTRB1 | CTSK 13/4885CTSS 2/4885CTSL 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.